Stagnant revenues for Pfizer this quarter

Pfizer sales flat at $11.97 billion, as profits triple on last year's huge Exubera discontinuation charge. Adjusted EPS would be 62 cents this year, up from 58 cents in 2007. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.